Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis
Authors
Keywords
-
Journal
Blood Advances
Volume 5, Issue 16, Pages 3163-3173
Publisher
American Society of Hematology
Online
2021-08-20
DOI
10.1182/bloodadvances.2020003829
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of myelofibrosis after ruxolitinib failure
- (2020) Claire N Harrison et al. ANNALS OF HEMATOLOGY
- Management of myelofibrosis after ruxolitinib failure
- (2020) Prithviraj Bose et al. LEUKEMIA & LYMPHOMA
- Luspatercept for the treatment of anemia in myelodysplastic syndromes (MDS) and primary myelofibrosis (PMF)
- (2019) Pierre Fenaux et al. BLOOD
- Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling
- (2019) Daniel A. C. Fisher et al. LEUKEMIA
- New Concepts of Treatment for Patients with Myelofibrosis
- (2019) Prithviraj Bose et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- SMAC mimetics as potential cancer therapeutics in myeloid malignancies
- (2019) Prajwal Boddu et al. BRITISH JOURNAL OF HAEMATOLOGY
- Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes and reduces bone marrow fibrosis in patients with myelofibrosis
- (2019) Naseema Gangat et al. CLINICAL CANCER RESEARCH
- Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors
- (2019) Minas P. Economides et al. Current Hematologic Malignancy Reports
- Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity
- (2019) Olli Dufva et al. BLOOD
- Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
- (2019) Francesca Palandri et al. CANCER
- Biomarker profile for prediction of response to SMAC mimetic monotherapy in pediatric precursor B‐cell acute lymphoblastic leukemia
- (2019) Julia Zinngrebe et al. INTERNATIONAL JOURNAL OF CANCER
- MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
- (2018) Paola Guglielmelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion
- (2018) William L. Heaton et al. LEUKEMIA
- Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial
- (2018) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
- (2017) Shawn T. Beug et al. Nature Communications
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- IAP antagonists induce anti-tumor immunity in multiple myeloma
- (2016) Marta Chesi et al. NATURE MEDICINE
- Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma
- (2016) Vijay Ramakrishnan et al. Oncotarget
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Rationale for combination therapy in myelofibrosis
- (2014) John Mascarenhas BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
- (2014) Jeffrey R. Infante et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Inhibitor of Apoptosis Proteins for Cancer Therapy: A Double-Edge Sword?
- (2014) Simone Fulda JOURNAL OF CLINICAL ONCOLOGY
- Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents
- (2014) Bing Z. Carter et al. JNCI-Journal of the National Cancer Institute
- Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma
- (2014) V Ramakrishnan et al. LEUKEMIA
- Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities
- (2014) S Fulda LEUKEMIA
- Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF- B Activation, and Is Active in Patient-Derived Xenograft Models
- (2014) C. A. Benetatos et al. MOLECULAR CANCER THERAPEUTICS
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Inhibitors of apoptosis proteins (IAPs) are required for effective T-cell expansion/survival during antiviral immunity in mice
- (2013) I. E. Gentle et al. BLOOD
- Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)
- (2013) Harry P. Erba et al. INVESTIGATIONAL NEW DRUGS
- Targeting IAP proteins for therapeutic intervention in cancer
- (2012) Simone Fulda et al. NATURE REVIEWS DRUG DISCOVERY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
- (2011) R. Scherber et al. BLOOD
- TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
- (2011) A. G. Fleischman et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- IAP inhibitors enhance co-stimulation to promote tumor immunity
- (2010) Michael Dougan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Smac mimetics: implications for enhancement of targeted therapies in leukemia
- (2010) E Weisberg et al. LEUKEMIA
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia
- (2009) Aaron D. Schimmer et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search